Tyra Biosciences (TYRA)
Developer of oral FGFR-targeted medicines for urothelial cancers and achondroplasia.
$25.38
vs last close−0.27 (−1.05%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 115.93% | 69.18M shares | |
|---|---|---|---|
| 177 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.86% | 1.71M shares | |
| 9 holders · as of Sep 17, 2026 | |||
| Strategic holders | 29.64% | 17.69M shares | |
| 3 holders · as of May 15, 2026 | |||
| Adds to | 148.43% | ||
59.68M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 148.43%; nothing is left for Other.
13F, as of Jun 30, 2026
177 holders · 69.18M shares · 36 new positions · 110 increased · 44 reduced · 25 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 12.20M | 20.44% | 0 | Aug 14, 2026 |
| FMR LLC | 8.92M | 14.95% | +1.17M | Aug 13, 2026 |
| Jupiter Topco LLC | 4.35M | 7.29% | +4.35Mnew | Aug 14, 2026 |
| Alta Partners Management Company, L.P. | 3.82M | 6.41% | 0 | Jul 22, 2026 |
| Nextech Invest, Ltd. | 3.55M | 5.95% | −502.3K | Aug 14, 2026 |
| TCG Crossover Management, LLC | 3.25M | 5.44% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 3.03M | 5.08% | +814.0K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 2.78M | 4.66% | +1.80M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Peter Kolchinskyincl. Rajeev Shah, RA Capital Healthcare Fund, L.P. +1 more | 19.90% | 14.13M | 13D | Sep 17, 2026 |
| FMR LLC | 14.40% | 7.75M | 13G | Apr 7, 2026 |
| Janus Henderson Group PLC | 7.20% | 3.89M | 13G | May 15, 2026 |
| Paradigm BioCapital Advisors LP | 5.80% | 3.47M | 13G | Sep 17, 2026 |
| TCG Crossover GP I, LLC | 5.70% | 2.90M | 13G | Mar 6, 2025 |
| Commodore Capital LP | 5.20% | 2.75M | 13G | May 14, 2025 |
| BlackRock, Inc. | 5.00% | 2.98M | 13G | Jul 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 15, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Purchase | 9,078,529 | $0.0010 | 11,616,986 |
| Sep 9, 2026 | Rehan Verjeedirector | Purchase | 972 | $20.58 | 972 |
| Mar 25, 2026 | Gilla Kaplandirector | Sale | 14,295 | $36.97 | 28,231 |
| Feb 12, 2026 | Daniel Bensenofficer: Chief Discovery Officer | Sale · 2 lots | 8,000 | $32.87 | 146,981 |
| Jan 12, 2026 | Daniel Bensenofficer: Chief Discovery Officer | Sale · 2 lots | 8,000 | $28.52 | 154,981 |
| Dec 19, 2025 | Robert J. Moredirector | Sale | 10,000 | $25.00 | 3,823,425 |
| Dec 12, 2025 | Daniel Bensenofficer: Chief Discovery Officer | Sale | 8,000 | $22.64 | 162,981 |
| Nov 21, 2025 | Robert J. Moredirector | Sale | 246,871 | $20.25 | 3,833,425 |
| Nov 19, 2025 | Daniel Bensenofficer: Chief Operating Officer | Sale | 49,956 | $16.32 | 170,981 |
| Nov 18, 2025 | Daniel Bensenofficer: Chief Operating Officer | Sale | 75,633 | $16.07 | 220,937 |
House and Senate disclosures
Not reported.